Skip to main content

Service

  • SmPC

Main navigation

  • Events &
    Resources
  • AZ Oncology
    Pipeline
AstraZeneca
E-Mail
Do you have any further questions or suggestions?
We look forward to your questions or feedback!

AstraZeneca AG

Responsible according to § 5 TMG
is the company AstraZeneca AG,
Neuhofstrasse 34,
6340 Baar, Schweiz


CH-8901 / 02-2024

Target group

The contents of this website are intended for HCPs from Switzerland.

Sitemap

Home Selectivity & MoA First Line R/R CLL Guidelines
Dosing Events & Resources On demand media AZ Oncology Pipeline

▼ This drug is subject to additional monitoring. For more information, see the Calquence product information on www.swissmedicinfo.ch.

Calquence®

C: Acalabrutinib; film coated tablets containing 100 mg acalabrutinib; List A. I: As monotherapy or in combination with Obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are 65 years of age or older or have comorbidities. As monotherapy for the treatment of adult patients with CLL who have received at least one prior therapy. P: 100 mg (1 tablet) twice daily, taken approximately 12 hours apart, with or without food. For recommended dose adjustments in the event of Grade ≥3 adverse effects: see www.swissmedicinfo.ch. It is not recommended to administer CALQUENCE in patients with severe hepatic impairment. CI: Hypersensitivity to the active substance or to any of the excipients. PR: Second primary malignancies, infections, haemorrhages, cytopenia, atrial fibrillation, tumour lysis syndrome (TLS). IA: Strong CYP3A modulators, substrates of BCRP (Breast Cancer Resistance Protein), substrates of MATE1 (e.g. metformin) AE: Calquence as monotherapy. Very common: Upper respiratory tract infection, sinusitis, second primary malignancy, neutropenia, anemia, decreased absolute neutrophil count, decreased haemoglobin, decreased platelet count, headache, dizziness/vertigo, bruising (contusion, petechiae), haemorrhage/haematoma, cough, diarrhoea, nausea, constipation, Abdominal pain, vomiting, rash, musculoskeletal pain, arthralgia, fatigue. Common: pneumonia, urinary tract infection, nasopharyngitis, bronchitis, herpes virus infections, sepsis, second primary malignancy excluding non-melanoma skin malignancy, non-melanoma skin malignancy, thrombocytopenia, atrial fibrillation/flutter, ecchymosis, gastrointestinal haemorrhage, intracranial haemorrhage, epistaxis, hypertension, asthenia. Calquence as combination therapy with Obinutuzumab. Very common: upper respiratory tract infection, sinusitis, pneumonia, urinary tract infection, nasopharyngitis, second primary malignancy, neutropenia, anaemia, thrombocytopenia, absolute neutrophil count decreased, haemoglobin decreased, platelet decreased, headache, dizziness/vertigo, bruising (contusion, petechiae), haemorrhage/haematoma, hypertension, cough, diarrhoea, nausea, constipation, abdominal pain, vomiting, rash, musculoskeletal pain, arthralgia, fatigue. Common: bronchitis, herpes viral infections, sepsis, second primary malignancy excluding non-melanoma skin malignancy, non-melanoma skin malignancy, atrial fibrillation/flutter, ecchymosis, gastrointestinal haemorrhage, intracranial haemorrhage, epistaxis, asthenia. Uncommon, rarely, very rarely: see www.swissmedicinfo.ch. Information as of May 2023. CH-7830 / 05-2023.

Additional Information: www.swissmedicinfo.ch or AstraZeneca AG, Neuhofstrasse 34, 6340 Baar. www.astrazeneca.ch.

Professionals can request the mentioned references from AstraZeneca AG.

Footer menu

  • Data privacy
  • Report side effects
  • Cookie policy
  • Terms of use
  • Contact us